Neurocognitive Enhancement in Major Depressive Disorder (MDDNET)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Christopher Bowie, Queen's University
ClinicalTrials.gov Identifier:
NCT00998569
First received: October 14, 2009
Last updated: March 20, 2012
Last verified: March 2012
  Purpose

The purpose of this study is to examine the effects of neurocognitive enhancement on cognitive abilities and related social and adaptive behaviours in individuals diagnosed with major depressive disorder. Subjects in this study will be randomized to receive Neurocognitive Enhancement Therapy (NET) or to a wait list and then NET . Secondary aims include examining whether the cognitive benefits are potentiated by repeated exposure during in-home practice with complementary exercises. Additionally, the investigators will examine the durability of the effects and their generalization to functional capacity and everyday functional performance after completion of the groups.


Condition Intervention
Major Depressive Disorder
Behavioral: Neurocognitive Enhancement
Behavioral: Wait List Control

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Neurocognitive Enhancement in Major Depressive Disorder

Resource links provided by NLM:


Further study details as provided by Queen's University:

Primary Outcome Measures:
  • Performance on paper and pencil assessments of neurocognition after treatment, compared to baseline assessment performance [ Time Frame: 20 weeks ] [ Designated as safety issue: No ]

Enrollment: 33
Study Start Date: October 2009
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Neurocognitive Enhancement Behavioral: Neurocognitive Enhancement
Neurocognitive Enhancement Therapy (NET) uses behavioural treatment strategies that are designed to improve a range of cognitive skills. NET uses strategies such as coaching, repetition, practice, teaching, group discussion, and compensation for deficits by using cognitive strengths.
No Intervention: Wait List Behavioral: Wait List Control
Participants will be wait listed for 10 weeks, following which time they will receive the intervention previously described.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or Female.
  2. Subjects will be between the ages of 18 and 65, which is the age range with available normative comparison data.

Exclusion Criteria:

  1. Presence of a medical diagnosis that is associated with known cognitive impairments, such as multiple sclerosis, cerebrovascular accident, dementia, or history of traumatic brain injury.
  2. Subjects with a reading level below grade 6, as assessed with the Wide Range Achievement Test - Reading Recognition Subtest, will be excluded because of the likelihood of not understanding task instructions.
  3. Subjects with uncorrectable vision or hearing impairment that would preclude valid assessments or intervention procedures.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00998569

Locations
Canada, Ontario
Queen's University
Kingston, Ontario, Canada, K7L 3N6
Sponsors and Collaborators
Queen's University
Investigators
Principal Investigator: Christopher Bowie, PhD Queen's University
  More Information

No publications provided

Responsible Party: Christopher Bowie, Ph.D., Queen's University
ClinicalTrials.gov Identifier: NCT00998569     History of Changes
Other Study ID Numbers: PSYC-092-09
Study First Received: October 14, 2009
Last Updated: March 20, 2012
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms

ClinicalTrials.gov processed this record on April 15, 2014